129 results about "Soluble immune complex" patented technology

The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

Aβ_N3pE-42 is a β amyloid protein that accumulates specifically as a major constituent of senile plaque in the brains of both sporadic and familial Alzheimer's disease patients. The invention provides antibodies that specifically recognize Aβ_N3pE-42 and can be expected to have a strong β amyloid-removing action. Particularly, humanized antibodies against Aβ_N3pE-42 are useful to treat human neurodegenerative diseases. Further, since Aβ_N3pE-42 is localized in the brain, the antibodies of the invention can avoid side effects such as kidney disorders caused by the formation of antigen-antibody complex in the blood. An agent for gene therapy using a vector in which a cDNA encoding a protein comprises the antigen-binding region of the antibody can be an efficient therapeutic drug for removing β amyloid from the brain.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity of P. falciparum, under conditions allowing an in vitro immunological reaction to occur between said composition and the antibodies that may be present in the tissue or biological fluid, and in vitro detection of the antigen-antibody complexes formed. The invention further relates to a polypeptide comprising at least one T epitope from a liver-stage specific protein produced by P. falciparum and a vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of P. falciparum in the hepatic cells.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The present invention is a method for the characterization or detection of one or more antibodies in a sample. The method comprises obtaining a tagged antigen comprising an antigen and a mass tag attached to the antigen. The tagged antigen has specificity for the antibody. In addition, the method comprises combining the tagged antigen with the antibody to form a tagged antigen-antibody complex. Further, the method comprises cleaving the mass tag from the tagged antigen-antibody complex. Thereafter, the method comprises analyzing the mass tag via a mass spectrometer to determine the presence of the mass tag in the sample and correlating the presence of the mass tag with a presence of the antibody in the sample.

The invention provides an aflatoxin B1 (AFB1) magnetic separation enzyme-linked immunity quantitative detection method, belonging to the field of food safety immunoassay technique. The method adopts the immuno-detection principle of competition law; and AFB1 is connected with biological enzyme to prepare enzyme-labeled antigen reagent, anti-fluorescein isothiocyanate (FITC) antibody is absorbed onthe surfaces of magnetic particles to prepare magnetic separation reagent, and the FITC is connected with the AFB1 antibody to prepare anti-reagent. In a sample, the AFB1 competes with the enzyme-labeled AFB1 and is combined with a small amount of FITC-labeled anti-AFB1 antibody, so that antigen-antibody complex can be formed. After the magnetic separation reagent is added, the complex is caughtonto the surfaces of the magnetic particles by the anti-FITC antibody connected on the surfaces of the magnetic particles. After being washed, the product is finally added with substrate and detected.The method has the advantages that (1) the magnetic particles are used for replacing the traditional enzyme-labeled plate to be taken as a solid-phase carrier, so that immunoreaction is carried out under the approximate liquid phase condition; and the reaction is more complete and rapid, and has the characteristics of high specificity and good repeatability compared with the traditional enzyme-linked immuno sorbent assay (ELISA); furthermore, (2) by adopting one-step competition law principle, the time used for detection is short.

The invention features a method of inhibiting tumor growth and/or tumor invasiveness in a mammal by administering to a mammal a compound (e.g., an antagonistic antibody) which inhibits expression or enzymatic activity of human aspartyl (asparaginyl) beta-hydroxylase (HAAH). The invention also features a method for diagnosing the growth of a malignant neoplasm (e.g., pancreatic cancer) in a mammal by contacting a tissue or bodily fluid from the mammal with an antibody which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and/or detecting the antigen-antibody complex.

The invention discloses an antigen antibody complex dissociation liquid kit, which is prepared by blending reagents of 0.3 volume percent of Triton-X100, 1.5 volume percent of lauryl sodium sulfate and 1.5 volume percent of 3-[(3-cholane amidopropyl)-dimethylammonium]propanesulfonic acid in equal amount. The invention also discloses application of the kit in separating a pathogenic antigen antibody complex. The kit of the invention effectively realizes rapid dissociation of the pathogenic antigen antibody complex in a serum or blood plasma sample to be detected, increases the absolute concentration value of an antigen and an antibody, and greatly improves the detection sensitivity of the sample to be detected.

The invention relates to the field of bioengineering, and specifically relates to a novel humanized anti-CD22 antibody. The novel humanized anti-CD22 antibody takes a murine antibody RFB4 as a parental antibody and uses a CDR implantation technique to carry out humanization; and the humanized new antibody hRFB4 has affinity similar with the parental antibody, and keeps the bonding capability of the parental antibody with the CD22 antigen and the cell internalizing activity of antigen-antibody complex caused by the antibody. Compared with the parental antibody, the humanized protein sequence proportion in the humanized hRFB4 antibody reaches over 90%, so that the immunogenicity is greatly reduced and the occurrence of HAMA reaction is avoided.

The present invention discloses a method for detecting third type hepatitis virus antibody by using magnetic micro-particle as transporting species which includes steps as follows: (1) using magnetic micro-particle as transporting species for reacting and separating, coupling third type hepatitis virus antibody on the magnetic micro-particle surface; (2) adding into confining liquid, oscillating 10 min with middle speed under condition of 20-40 deg c, magnetic separating, giving up supernatant; (3) combining the third type hepatitis virus antibody packed on the magnetic micro-particle surface with the specificity antibody on waited blood; (4) separating the magnetic micro-particle with specificity antigen-antibody complex on surface through an externally-applied magnetic field; (5) combining the antibody complex on the magnetic micro-particle surface with enzyme label rat mouse-anti-body IgG; (6) using chemiluminescence detector, irradiancy substrates A liquor and B liquor for detecting sample irradiancy value. The method has characteristics of rapid detecting speed, high specificity, stabilising, no radioactive pollution which can increase sensitivity and stabilizing ability for detecting.

The invention discloses a method for determining the differences of protein contents, which comprises the steps that: a. a plurality of kinds of protein antibodies respectively combined with different oligonucleotide sequences synchronously carry out antigen antibody reaction with one kind of proteantigen to be tested; b. the oligonucleotide sequences of the antigen antibody complex in the step a are coupled together through the coupled reaction by using ligase, and the sequences of a ligation product are led to contain a base sequence representing the source of the protein to be tested; c. the ligation product in the step b is taken as a templet, and a base sequence containing the specificity of the source of the protein to be tested is amplified by adopting the amplification reaction; d. the base sequence representing the source of the protein to be tested in the amplification product sequence is determined by adopting the real-time sequencing technology; and e. the sequence determined in the step d is taken as the source of the protein to be tested, signal intensity of each sequence is compared to obtain the relative contents of the protein to be tested in each source. The method can determine the differences of protein expression content from different sources at tone time with low cost.

The present invention provides one kind of Bt crystallin Cry lAc radioimmunoassay kit and its preparation process and detection method. Magnetic particle is prepared with glutaraldehyde, Aerosol 604 and ferroferric oxide, and connected to Bt crystallin Cry lAc antibody. Under the action of magnetic field, Bt crystallin Cry lAc and Bt crystallin Cry lAc antibody react specifically in fast speed and the sample testing period is reduced to 40 min. The present invention also connect magnetic particle to IgG to prepare immunological separating agent, and under the action of magnetic field, the antigen antibody composition deposits automatically for separation without needing centrifugation.

The invention belongs to an immunodetection field and specifically relates to an optimized co-immunoprecipitation technology. Based on an original co-immunoprecipitation technology, the co-immunoprecipitation technology is combined with a protein crosslink technology. That is to say, a protein crosslinking agent is used to crosslink an antigen antibody complex; elution is carried out by the use of a specific buffer; and the immunoblotting detection remarkably reduces the pollution of heavy chain and light chain of the antibody in the experiment. According to the invention, specificity of the co-immunoprecipitation method is raised, the method is characterized by stability and repeatability, experiment efficiency is improved, and the method provides beneficial assistance for in-depth research in molecular biology, molecular oncology, cell biology, biochemistry and the like.

The invention provides an antigen-antibody complex for preventing and/or treating avian influenza, which comprises inactivation avian influenza totiviruses which are used as antigen and an immune body thereof, and the mass concentration ratio of the antigen and the immune body is more than 1. After entering organisms to perform initial immunization, the antigen-antibody complex stimulates the organisms again to induce immunoreaction, and immune response is quick in speed and strong in reaction; the antigen-antibody complex used as a carrier is more favorable for capturing and presenting antigen presenting cells and can also strengthen a breeder reaction of T cells effectively; purified totiviruses used as the antigen increase the molecular weight of the complex, are more favorable for ingestion of immunocyte of the organisms on the antigen, cause the more extensive immunoreaction quickly, and have a significance for preventing avian influenza viruses of which the antigen is easy for variation. A preparation of the antigen-antibody complex does not need to use solid carriers, does not cause intense stimulus on the organisms or initiates the organisms to generate an adverse reaction, and is simple to prepare and safe and convenient to use.

A method for measuring a concentration of a β-amyloid antibody in a body fluid sample through a reaction forming an antigen-antibody complex uses an antigen protein binding specifically to the β-amyloid antibody existing in a body fluid of an Alzheimer's disease patient. A diagnostic kit for Alzheimer's disease using the method is also provided.

The invention relates to the technical field of medicine and biochemistry and particularly relates to a kit for determining myoglobin. The kit is composed of double reagents R1 and R2, wherein the reagent R1 is prepared from the following components: 15mmol/L-145mmol/L of a Tris buffering solution, 50mmol/L-200mmol/L of sodium chloride, 5g/L-20g/L of polyethylene glycol-8000, 0.4g/L-1.2g/L of sodium azide, 12g/L-32g/L of bovine serum albumin and a solvent which is a purified water; the reagent R2 is prepared from the following components: 50mmol/L-150mmol/L of a Tris buffering solution, 4g/L-26g/L of bovine serum albumin, 5g/L-15g/L of glycerol, 0.6g/L-1.2g/L of sodium azide, 1g/L-4g/L of an emulsion-coated anti-human myoglobin antibody and a solvent which is purified water. Myoglobin (MYO) in the sample can be combined with the corresponding specific anti-MYO antibody in the reagent R2 to form an antigen-antibody complex and certain turbidity is generated. The turbidity level and the content of an antigen form a direct proportion when the certain antibody exists. The turbidity is determined under a certain wavelength and quantitative determination of the myoglobin can be carried out through a multi-point calibration curve. The kit has the advantages of high accuracy, convenient operation and the like.

The invention discloses an application of a Glypican-1 protein in the diagnosis of pancreatic cancer, a detection method of a Glypican-1 positive exosome concentration, and a use of the detection method. A nano-plasma enhanced scattering (nPES) detection technology can be used to quantify exosomes in serum, an exosome extracting process is omitted, the characteristic antigen of the exosomes is used as a target, and the antigen and a corresponding antibody carrying gold nanoparticles form an antigen-antibody complex in order to obtain exosomes, and the amount of the exosomes is reflected by using the light radiation principle of the gold nanoparticles. The Glypican-1 is a pancreatic cancer-derived exosome biomarker, and the content of Glypican-1 positive exosomes in blood plasma has specific specificity even in early pancreatic cancer, so the exosome content index can be used to diagnose the pancreatic cancer, and the exosome level is closely related to the staging and progression of pancreatic cancer patients. Experiments prove that the method using the nPES detection technology to detect the content of the Glypican-1 exosomes in the serum is concise and accurate, and has better sensitivity and specificity than CA19-9 in the diagnosis of the pancreatic cancer.

This invention discloses one method to test hepatitis C virus total nuclear antigen, which hcomprises the following steps: testing front protein transformation agent and non-ion surface activity agent to pre-process this sample; then adopting hepatitis C to test the nuclear antigen enzyme immune dialogue case. This invention pre-process can impact Ig molecule transformation area especially long area to reduce its combination opportunity with antigen to promote antigen compound isolation and to make the nuclear antigen fully exposed.

The invention relates to a new-drug molecule designing method based on stereochemical structure information by the action of antigen and antibody. Concretely speaking, it designs theoretical conformation of changeable region of antigen and antibody on the computer, on this basis builds the theoretical conformation of antigen-antibody complex, identifies epitope in antigen combined with antibody and verifies the epitope by experiment, and designs a new-drug molecule according to the sequence of the epitope.

The invention discloses a method for rapidly preparing a chromatin immunoprecipitation sample. The method comprises the following steps: performing formaldehyde crosslinking on a cell to fix a complex of a protein and a nucleic acid, extracting the complex of the protein and the nucleic acid, and breaking a chromatin segment into small segments in an ultrasonic or enzymatic hydrolysis manner; suspending an antibody onto a solid-phase support, i.e. a magnetic bead, adding the obtained small segments onto the prepared magnetic bead, performing incubation to obtain a magnetic bead antigen antibody complex, washing an uncombined substance away after incubation is finished, and resuspending the magnetic bead antigen antibody complex to obtain a magnetic bead antigen antibody complex sample to be detected. The method is easy to operate; the prepared magnetic bead antigen antibody complex sample can be directly used for PCR detection or amplification and construction of a DNA library, so that the sample preparation time is obviously shortened, meanwhile, the shortcoming of weaker enrichment signals of certain proteins and DNAs caused by excessive elution steps is overcome, the detection sensitivity is greatly improved, and influence on subsequent PCR identification and DNA segment amplification is avoided.